Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

On to the clinic
February 2020
SHARING OPTIONS:

GROSSE POINTE FARMS, Mich.—SciTech Development's Investigational New Drug (IND) application for ST-001 nanoFenretinide was accepted by the U.S. Food and Drug Administration, SciTech announced recently. This clears ST-001 nanoFenretinide, an experimental treatment for T-cell non-Hodgkin's lymphoma (NHL), to enter clinical trials. The first study will be conducted at the Rush University Medical Center, and will consist of patients with relapsed/refractory T-cell NHL, with a scheduled start date of mid-2020. ST-001 nanoFenretinide features a nanoparticle suspension to allow for intravenous administration.
 
Earle Holsapple, president of SciTech Development, commented in part that “FDA approval of our IND for ST-001 is a significant milestone in the development of our SciTech Drug Delivery Vehicle (SDV) program.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.